全文获取类型
收费全文 | 321055篇 |
免费 | 19354篇 |
国内免费 | 579篇 |
专业分类
耳鼻咽喉 | 4404篇 |
儿科学 | 10851篇 |
妇产科学 | 10702篇 |
基础医学 | 48563篇 |
口腔科学 | 7752篇 |
临床医学 | 26446篇 |
内科学 | 61717篇 |
皮肤病学 | 6632篇 |
神经病学 | 23491篇 |
特种医学 | 12467篇 |
外国民族医学 | 44篇 |
外科学 | 51371篇 |
综合类 | 7925篇 |
现状与发展 | 1篇 |
一般理论 | 169篇 |
预防医学 | 21437篇 |
眼科学 | 7228篇 |
药学 | 22408篇 |
中国医学 | 863篇 |
肿瘤学 | 16517篇 |
出版年
2021年 | 2697篇 |
2019年 | 2826篇 |
2018年 | 4251篇 |
2017年 | 3141篇 |
2016年 | 3599篇 |
2015年 | 4106篇 |
2014年 | 5440篇 |
2013年 | 8388篇 |
2012年 | 10823篇 |
2011年 | 11360篇 |
2010年 | 7288篇 |
2009年 | 6651篇 |
2008年 | 10358篇 |
2007年 | 11264篇 |
2006年 | 10981篇 |
2005年 | 10652篇 |
2004年 | 10168篇 |
2003年 | 9693篇 |
2002年 | 9313篇 |
2001年 | 13534篇 |
2000年 | 13829篇 |
1999年 | 11665篇 |
1998年 | 3356篇 |
1997年 | 3105篇 |
1996年 | 2856篇 |
1995年 | 2761篇 |
1994年 | 2515篇 |
1992年 | 8446篇 |
1991年 | 8568篇 |
1990年 | 8371篇 |
1989年 | 8160篇 |
1988年 | 7397篇 |
1987年 | 7138篇 |
1986年 | 6820篇 |
1985年 | 6600篇 |
1984年 | 4850篇 |
1983年 | 4208篇 |
1982年 | 2568篇 |
1979年 | 4481篇 |
1978年 | 3273篇 |
1977年 | 2769篇 |
1976年 | 2539篇 |
1975年 | 2868篇 |
1974年 | 3389篇 |
1973年 | 3394篇 |
1972年 | 3143篇 |
1971年 | 2969篇 |
1970年 | 2854篇 |
1969年 | 2597篇 |
1968年 | 2548篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
3.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
4.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献5.
6.
7.
8.
9.
Ingmar Fleps Pierre Guy Stephen J Ferguson Peter A Cripton Benedikt Helgason 《Journal of bone and mineral research》2019,34(10):1837-1850
The majority of hip fractures in the elderly are the result of a fall from standing or from a lower height. Current injury models focus mostly on femur strength while neglecting subject-specific loading. This article presents an injury modeling strategy for hip fractures related to sideways falls that takes subject-specific impact loading into account. Finite element models (FEMs) of the human body were used to predict the experienced load and the femoral strength in a single model. We validated these models for their predicted peak force, effective pelvic stiffness, and fracture status against matching ex vivo sideways fall impacts (n = 11) with a trochanter velocity of 3.1 m/s. Furthermore, they were compared to sideways impacts of volunteers with lower impact velocities that were previously conducted by other groups. Good agreement was found between the ex vivo experiments and the FEMs with respect to peak force (root mean square error [RMSE] = 10.7%, R2 = 0.85) and effective pelvic stiffness (R2 = 0.92, RMSE = 12.9%). The FEMs were predictive of the fracture status for 10 out of 11 specimens. Compared to the volunteer experiments from low height, the FEMs overestimated the peak force by 25% for low BMI subjects and 8% for high BMI subjects. The effective pelvic stiffness values that were derived from the FEMs were comparable to those derived from impacts with volunteers. The force attenuation from the impact surface to the femur ranged between 27% and 54% and was highly dependent on soft tissue thickness (R2 = 0.86). The energy balance in the FEMS showed that at the time of peak force 79% to 93% of the total energy is either kinetic or was transformed to soft tissue deformation. The presented FEMs allow for direct discrimination between fracture and nonfracture outcome for sideways falls and bridge the gap between impact testing with volunteers and impact conditions representative of real life falls. © 2019 American Society for Bone and Mineral Research. 相似文献
10.